iShares Biotechnology ETF (IBB)
| Assets | $8.35B |
| Expense Ratio | 0.44% |
| PE Ratio | 12.93 |
| Shares Out | 66.35M |
| Dividend (ttm) | $0.35 |
| Dividend Yield | 0.28% |
| Ex-Dividend Date | Mar 23, 2023 |
| Payout Ratio | 4.26% |
| 1-Year Return | -3.36% |
| Volume | 1,228,014 |
| Open | 124.41 |
| Previous Close | 124.35 |
| Day's Range | 123.42 - 126.16 |
| 52-Week Low | 104.29 |
| 52-Week High | 138.74 |
| Beta | 0.85 |
| Holdings | 276 |
| Inception Date | Feb 5, 2001 |
About IBB
The iShares Biotechnology ETF (IBB) is an exchange-traded fund that is based on the ICE Biotechnology index. The fund tracks the performance of a modified market-cap-weighted index of US biotechnology companies listed on US exchanges. IBB was launched on Feb 5, 2001 and is managed by BlackRock.
Top 10 Holdings
53.67% of assets| Name | Symbol | Weight |
|---|---|---|
| Amgen Inc. | AMGN | 8.18% |
| Gilead Sciences, Inc. | GILD | 7.97% |
| Regeneron Pharmaceuticals, Inc. | REGN | 7.65% |
| Vertex Pharmaceuticals Incorporated | VRTX | 7.58% |
| Moderna, Inc. | MRNA | 4.92% |
| Biogen Inc. | BIIB | 3.74% |
| Seagen Inc. | SGEN | 3.62% |
| IQVIA Holdings Inc. | IQV | 3.48% |
| Illumina, Inc. | ILMN | 3.40% |
| Mettler-Toledo International Inc. | MTD | 3.14% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 23, 2023 | $0.060 | Mar 29, 2023 |
| Dec 13, 2022 | $0.1014 | Dec 19, 2022 |
| Sep 26, 2022 | $0.15859 | Sep 30, 2022 |
| Jun 9, 2022 | $0.03053 | Jun 15, 2022 |
| Mar 24, 2022 | $0.11756 | Mar 30, 2022 |
| Dec 13, 2021 | $0.04129 | Dec 17, 2021 |
News
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
Smart Beta ETF report for IBB
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.
Should You Invest in the iShares Biotechnology ETF (IBB)?
Sector ETF report for IBB
Regional banks pace decliners, as biotech deals lift Seagen and Provention Bio
Here are some of the biggest movers on Monday with banks firmly in focus after federal regulators stepped into protect deposits at fallen bank SVB.
SVB fallout: The impacts on the biotech sector
CNBC's Meg Tirrell reports on how the SVB fallout could impact biotech investors.
The Recent Bullish Trend in IBB, XBI Looks Shaky
Rising interest rates taking steam from rally that powered in IBB and XBI.
5 Least-Hurt Biotech ETFs of the Last Week
Rising rate worries have weighed on the biotech sector. However, these biotech ETFs still have lost the least in recent days.
Analysis: Biotech IPOs to bloom with spotlight on startups with human trial data
Initial public offerings by small private biotech companies are poised to stage a comeback later in 2023 as the pace of interest rate hikes slows, but tougher economic conditions will make investors m...
Pharmaceutical companies losing patent protection as competition grows
The Wall Street Journal's Jared Hopkins joins 'Power Lunch' to discuss biotech patent protection duration, competition coming to the pharmaceutical industry and pharmaceutical M&A plans.
There's a crop of great biotech companies ready to be acquired, says MPM's Christiana Bardon
Dr. Christiana Bardon, co-managing partner of MPM's BioImpact Capital, joins 'The Exchange' to discuss tailwinds in the pharmaceutical and biotech sector, innovation in obesity drugs, and acquisition ...
Why Biotech Is Poised for a Recovery This Year
Pharma and biotech stocks moved in opposite directions last year, but fortunes are shifting.
Biotech's Blockbuster Week: 3 Stocks to Watch
In a strong week for the market, biotech dominated. Today we will cover 3 promising stocks in the space.
Subversive Launches ETF to Focus on Mental Health
The debut highlights the lack of funds focused on the area.
JPMorgan's bullish call on biopharma
The "Halftime Report" traders debate the biggest analyst calls of the day.
Final Trades: IBB, META, TSM & LVS
The traders make their final trades of the week. With CNBC's Dominic Chu and the Fast Money traders, Tim Seymour, Courtney Garcia, Steve Grasso and Jeff Mills.
ETFs Find a Role in a Long-Term Portfolio
Albion Financial's Jason Ware sees funds as mainstays in ‘core-satellite' planning.
We still think there's more room for biotech to go higher, says Jefferies' Yee
Michael Yee, Jefferies managing director, joins 'Power Lunch' to discuss what's behind the general move higher in biotech stocks, why biotech stocks were under-owned not long ago and if it's too late ...
If we do enter a recession next year, we'll see more of a rotation into health care, says RTW's Wong
Dr. Rod Wong, RTW Investments managing partner and CIO, joins the 'Halftime Report' to discuss his thoughts on the biotech sector going into the new year, his investing thesis behind Avidity Bioscienc...
How Are Biotech ETFs Reacting to Q3 Earnings Releases?
Biotech earnings have come in upbeat in the third quarter.
XBI vs IBB: what's a better way to play the biotech space?
Biotech will continue to outperform the benchmark since the U.S. economy is currently in late-cycle expansion, says Bryn Talkington. She's a Managing Partner at Requisite Capital Management.
Final Trades: Biotech, Treasuries & more
The "Halftime Report" traders give their top picks to watch for the second half.
Biotech is going to have a hard time until the end of rate cycle, says E Squared's Les Funtleyder
Les Funtleyder, E Squared Capital Management portfolio manager, joins 'Power Lunch' to discuss his favorite stocks for Q4, how long it'll be until the small- and mid-cap biotech stocks move higher and...